VIA EDGAR
June 3, 2024
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Ms. Tamika Sheppard
| Re: | Nektar Therapeutics | |||
| Acceleration Request for Registration Statement on Form S-3 | ||||
| File No. 333-279760 | ||||
| Acceleration Request | ||||
| Requested Date: | June 5, 2024 | |||
| Requested Time: | 4:05 p.m., Eastern Time | |||
Dear Ms. Sheppard:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Nektar Therapeutics (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to June 5, 2024, at 4:05 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Sam Zucker at (650) 752-3232.
If you have any questions regarding this request, please contact Sam Zucker of Goodwin Procter LLP at (650) 752-3232.
| Sincerely, |
| NEKTAR THERAPEUTICS |
| /s/ Mark A. Wilson |
| Mark A. Wilson |
| General Counsel |
| Nektar Therapeutics |
| cc: | Howard W. Robin, Chief Executive Officer, President and Director, Nektar Therapeutics Sandra Gardiner, Chief Financial Officer, Nektar Therapeutics Mitchell S. Bloom, Esq., Goodwin Procter LLP Sam Zucker, Esq., Goodwin Procter LLP |